Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

Completed

• Conditions: Urinary Infections

• Registration Number: NCT00195286
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections

Detailed Description

Not available

Study Timeline

• Study Start: 2004-06
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Primary Completion: 2007-07
• Study Completion: 2007-07
• Status Verified: 2009-09
• Last Update Submitted: 2009-09-24
• Last Update Posted: 2009-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria

• Patients known, or thought to be hypersensitivity to beta-lactams
• Patients with an uncomplicated urinary tract infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified